MCID: SKN019
MIFTS: 68

Skin Melanoma

Categories: Cancer diseases, Ear diseases, Skin diseases

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma 12 54 15
Cutaneous Melanoma 12 15 71
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Melanoma, Cutaneous Malignant 43
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8923
ICD9CM 34 172.9
MeSH 43 C562393
NCIt 49 C3510
SNOMED-CT 67 93655004
ICD10 32 C43 C43.9
UMLS 71 C0025202 C0151779

Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 1 and skin carcinoma, and has symptoms including pruritus and exanthema. An important gene associated with Skin Melanoma is LINC00937 (Long Intergenic Non-Protein Coding RNA 937), and among its related pathways/superpathways are ERK Signaling and Apoptotic Pathways in Synovial Fibroblasts. The drugs Vindesine and Pravastatin have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 505)
# Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 1 34.5 TYR TP53 PTEN PMEL NRAS MITF
2 skin carcinoma 33.3 TYR TP53 NRAS CDKN2A CASP3
3 acral lentiginous melanoma 32.9 PTEN NRAS CDKN2A BRAF
4 amelanotic melanoma 32.9 TYR MITF BRAF
5 spitzoid melanoma 32.8 NRAS CDKN2A BRAF
6 melanoma in congenital melanocytic nevus 32.5 TYR TP53 PMEL NRAS MITF CDKN2A
7 mucosal melanoma 31.4 NRAS MITF CDKN2A BRAF
8 keratosis 31.3 TYR TP53 MMP2 CDKN2A
9 familial retinoblastoma 31.2 TP53 MDM2 CDKN2A
10 lentigo maligna melanoma 31.1 MMP2 MITF
11 vitiligo-associated multiple autoimmune disease susceptibility 1 31.1 TYR PMEL MITF FGF2
12 lentigines 31.1 TYR MITF BRAF
13 spitz nevus 31.1 TP53 CDKN2A BRAF
14 melanoma 31.1 TYR TP53 PTEN PMEL NRAS MMP2
15 actinic keratosis 31.0 TYR TP53 MMP2 MITF CDKN2B CDKN2A
16 retinoblastoma 30.9 TP53 MDM2 CDKN2B CDKN2A CDKN1A CASP3
17 nodular malignant melanoma 30.9 TYR TP53 NRAS MITF CDKN2A BRAF
18 hereditary melanoma 30.8 MDM2 CDKN2A
19 basal cell carcinoma 30.8 TYR TP53 PTEN CDKN2B CDKN2A CDKN1A
20 in situ carcinoma 30.7 TP53 PTEN ERBB2 CDKN2A
21 diffuse large b-cell lymphoma 30.7 TP53 PTEN MDM2 CDKN2A
22 connective tissue cancer 30.7 TP53 PTEN MDM2 CDKN2A
23 b-cell lymphoma 30.7 TP53 MDM2 CDKN2B CDKN2A CDKN1A CASP3
24 epithelioid cell melanoma 30.7 TYR MITF
25 meningioma, familial 30.7 TP53 PTEN ERBB2 CDKN2A
26 lymphoma, non-hodgkin, familial 30.6 TP53 PTEN NRAS MDM2 CDKN2B CDKN2A
27 squamous cell carcinoma 30.6 TP53 PTEN MMP2 ERBB2 CDKN2A CDKN1A
28 li-fraumeni syndrome 30.6 TP53 PTEN MDM2 ERBB2 CDKN2B CDKN2A
29 actinic cheilitis 30.6 TP53 MDM2 CDKN1A
30 cheilitis 30.6 TP53 MDM2 CDKN1A
31 halo nevi 30.6 TYR PMEL
32 kidney cancer 30.6 TP53 PTEN FGF2 CDKN2A CDKN1A
33 vascular cancer 30.6 TP53 MITF FGF2
34 lip cancer 30.5 TP53 MDM2 CDKN1A BRAF
35 osteogenic sarcoma 30.5 TP53 MMP2 MDM2 CDKN2A CDKN1A CASP3
36 lymphoma 30.5 TP53 NRAS MDM2 CDKN2B CDKN2A CASP3
37 ductal carcinoma in situ 30.5 TP53 PTEN ERBB2 CDKN2A
38 neurofibroma 30.5 TYR TP53 PTEN MITF CDKN2A
39 gastrointestinal stromal tumor 30.5 TP53 PTEN MMP2 ERBB2 CDKN2A CDKN1A
40 cellulitis 30.5 TYR PMEL MITF
41 fibrosarcoma 30.5 TP53 MMP2 FGF2 CDKN1A
42 skin squamous cell carcinoma 30.5 TP53 PTEN NRAS CDKN2A BRAF
43 small cell carcinoma 30.5 TP53 PTEN CDKN2A
44 oligodendroglioma 30.5 TP53 PTEN MDM2 CDKN2B CDKN2A
45 pancreatic cancer 30.4 TP53 PTEN MMP2 FGF2 ERBB2 CDKN2A
46 leukemia, chronic lymphocytic 30.4 TP53 PTEN NRAS MDM2 ERBB2 CDKN2B
47 endometrial adenocarcinoma 30.4 TP53 PTEN FGF2 ERBB2 CDKN2A
48 liposarcoma 30.4 TP53 PTEN MDM2 CDKN2A CASP3
49 papilloma 30.4 TP53 PTEN CDKN2B CDKN2A CDKN1A
50 rhabdomyosarcoma 30.4 TP53 PTEN MDM2 CDKN2A CDKN1A

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


pruritus, exanthema

MGI Mouse Phenotypes related to Skin Melanoma:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
2 behavior/neurological MP:0005386 10.45 BRAF CASP3 CDKN1A CDKN2A ERBB2 FGF2
3 cardiovascular system MP:0005385 10.44 BRAF CASP3 CDKN1A CDKN2A ERBB2 FGF2
4 cellular MP:0005384 10.44 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
5 hematopoietic system MP:0005397 10.42 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
6 endocrine/exocrine gland MP:0005379 10.41 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
7 integument MP:0010771 10.39 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
8 growth/size/body region MP:0005378 10.37 BRAF CASP3 CDKN1A CDKN2A ERBB2 MDM2
9 immune system MP:0005387 10.37 BRAF CASP3 CDKN1A CDKN2A CDKN2B MCAM
10 mortality/aging MP:0010768 10.36 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
11 craniofacial MP:0005382 10.32 BRAF CASP3 CDKN1A ERBB2 MDM2 MITF
12 embryo MP:0005380 10.3 BRAF CDKN1A CDKN2A ERBB2 MDM2 MITF
13 digestive/alimentary MP:0005381 10.26 BRAF CASP3 CDKN1A CDKN2A ERBB2 MDM2
14 neoplasm MP:0002006 10.26 BRAF CDKN1A CDKN2A CDKN2B ERBB2 FGF2
15 nervous system MP:0003631 10.23 BRAF CASP3 CDKN1A CDKN2A ERBB2 FGF2
16 limbs/digits/tail MP:0005371 10.19 BRAF CDKN1A ERBB2 MDM2 MITF NRAS
17 muscle MP:0005369 10.19 BRAF CASP3 CDKN1A CDKN2A ERBB2 FGF2
18 no phenotypic analysis MP:0003012 10.17 CASP3 CDKN1A CDKN2A CDKN2B MCAM MDM2
19 hearing/vestibular/ear MP:0005377 10.13 BRAF CASP3 CDKN1A FGF2 MITF TP53
20 liver/biliary system MP:0005370 10.13 BRAF CDKN1A CDKN2A MDM2 MITF NRAS
21 pigmentation MP:0001186 10.07 BRAF CASP3 CDKN2A MDM2 MITF NRAS
22 normal MP:0002873 10.06 BRAF ERBB2 MDM2 MITF MMP2 NRAS
23 reproductive system MP:0005389 10.03 BRAF CASP3 CDKN1A CDKN2A CDKN2B ERBB2
24 renal/urinary system MP:0005367 9.97 BRAF CASP3 CDKN1A CDKN2B MDM2 MITF
25 skeleton MP:0005390 9.8 BRAF CASP3 CDKN1A CDKN2A ERBB2 FGF2
26 respiratory system MP:0005388 9.76 BRAF CASP3 CDKN1A CDKN2A ERBB2 MMP2
27 vision/eye MP:0005391 9.4 BRAF CASP3 CDKN1A CDKN2A FGF2 MITF

Drugs & Therapeutics for Skin Melanoma

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 635)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
2
Pravastatin Approved Phase 4 81093-37-0 54687
3
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
4
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
5
Infliximab Approved Phase 4 170277-31-3
6
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
9
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Aminolevulinic acid Approved Phase 4 106-60-5 137
12
Fluorouracil Approved Phase 4 51-21-8 3385
13
Menthol Approved Phase 4 2216-51-5 16666
14
Etanercept Approved, Investigational Phase 4 185243-69-0
15
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
16
Adalimumab Approved Phase 4 331731-18-1 16219006
17
Tofacitinib Approved, Investigational Phase 4 477600-75-2
18
Cabergoline Approved Phase 4 81409-90-7 54746
19
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
20
Sunitinib Approved, Investigational Phase 4 557795-19-4, 341031-54-7 5329102
21
Theobromine Investigational Phase 4 83-67-0 5429
22
Epicatechin Investigational Phase 4 490-46-0, 35323-91-2 72276
23 Salicylates Phase 4
24 Antirheumatic Agents Phase 4
25 Gastrointestinal Agents Phase 4
26 Cyclosporins Phase 4
27 Psychotropic Drugs Phase 4
28 Antidepressive Agents Phase 4
29 Fibrin Tissue Adhesive Phase 4
30 Coagulants Phase 4
31 Serotonin Uptake Inhibitors Phase 4
32 Viscosupplements Phase 4
33 Monoamine Oxidase Inhibitors Phase 4
34 Photosensitizing Agents Phase 4
35 Methyl 5-aminolevulinate Phase 4
36 Dopamine agonists Phase 4
37 Antiparkinson Agents Phase 4
38 Anesthetics Phase 4
39 Anesthetics, Local Phase 4
40 Daminozide Phase 4 1596-84-5
41 Protein Kinase Inhibitors Phase 4
42
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
43
Timolol Approved Phase 3 26839-75-8 5478 33624
44
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
45
Bevacizumab Approved, Investigational Phase 3 216974-75-3
46
Peginterferon alfa-2a Approved, Investigational Phase 3 198153-51-4 5360545
47
Ethanol Approved Phase 3 64-17-5 702
48
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
49
Sufentanil Approved, Investigational Phase 3 56030-54-7 41693
50
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158

Interventional clinical trials:

(show top 50) (show all 3053)
# Name Status NCT ID Phase Drugs
1 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Unknown status NCT02626065 Phase 4 Nivolumab
2 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
3 A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma Unknown status NCT00540930 Phase 4 Ranibizumab
4 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
5 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
6 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
7 An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa. Completed NCT01898585 Phase 4 Zelboraf
8 Neoadjuvant GM-CSF Treatment and Modulation of Immune Cell Profile of the SLN in Melanoma Completed NCT02451488 Phase 4 GM-CSF
9 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
10 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
11 Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial. Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
12 IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
13 Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
14 An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer Completed NCT00198276 Phase 4
15 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
16 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
17 A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors Completed NCT00075166 Phase 4
18 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. Completed NCT00640159 Phase 4 Zelapar
19 An Evaluation of the Efficacy of the Tumor Necrosis Factor-alpha Antagonist Infliximab in Treatment Resistant Major Depression: Mechanisms and Mediators Completed NCT00463580 Phase 4 Infliximab;Placebo
20 A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites Completed NCT01722994 Phase 4
21 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
22 A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
23 Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial Recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
24 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
25 Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial Recruiting NCT03909646 Phase 4 Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram;5Fluorouracil
26 Phase IV Ipilimumab in Melanoma: A National, Multicenter, Interventional Study in Patients With Unresectable or Metastatic Melanoma Active, not recruiting NCT02068196 Phase 4 Ipilimumab
27 PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS Active, not recruiting NCT02092467 Phase 4 tofacitinib;tofacitinib
28 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
29 COcoa Supplement and Multivitamin Outcomes Study Active, not recruiting NCT02422745 Phase 4
30 Influenza Vaccine Responses in the Setting of Melanoma Treatment Enrolling by invitation NCT03315975 Phase 4
31 An Exploratory Prospective, Open-label, Unicentric Study With Cross-over Design, Comparing Lymphoseek® vs. Albumin Nanocolloid for Image- Guided Sentinel Lymph Node Mapping in Head and Neck, Melanoma and Breast Cancer. Not yet recruiting NCT04261179 Phase 4 Lymphoseek;Nanocoll
32 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1) Not yet recruiting NCT03313544 Phase 4 Nivolumab
33 Randomized Trial of Bupivacaine as Adjuvant for Post-operative Pain in Mohs Micrographic Surgery Not yet recruiting NCT04362566 Phase 4 Bupivacaine
34 Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
35 A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
36 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
37 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
38 Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
39 Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation Unknown status NCT00005052 Phase 3
40 A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma Unknown status NCT00052156 Phase 3
41 Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma Unknown status NCT00052130 Phase 3
42 Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts Unknown status NCT00002455 Phase 3
43 PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA Unknown status NCT00002767 Phase 3
44 Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma. Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
45 POST-OPERATIVE ADJUVANT INTERFERON-ALFA-2B (INTRON-A) TREATMENT AFTER RESECTION OF THICK PRIMARY MELANOMA AND/OR REGIONAL LYMPHNODE METASTASES 'INTERMEDIATE-HIGH DOSE' VS INTERMEDIATE-LOW DOSE' IFN-ALFA VS OBSERVATION: A 3-ARM MULTICENTER RANDOMIZED PHASE III TRIAL Unknown status NCT00002763 Phase 3
46 Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients Unknown status NCT01861938 Phase 2, Phase 3
47 PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial Unknown status NCT00006249 Phase 3
48 A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients Unknown status NCT02938299 Phase 3 L19IL2 + L19TNF
49 A Multicenter, Randomized, Controlled, Phase III Trial Comparing High-Dose IFN-a2b With Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma Unknown status NCT03435302 Phase 3 Temozolomide Plus Cisplatin;High-Dose IFN-a2b
50 A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis Unknown status NCT00039234 Phase 3 histamine dihydrochloride

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
Carmustine
dabrafenib
Dacarbazine
docetaxel
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
peginterferon alfa-2a
peginterferon alfa-2b
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
temozolomide
trametinib
Vemurafenib

Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

40
Skin, Lymph Node, Lung, T Cells, Brain, Breast, Testes

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 7533)
# Title Authors PMID Year
1
Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. 61 54
15960923 2005
2
The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival. 61 54
11268486 2000
3
Differential expression of nm23 H-1 protein in conjunctival melanoma and potential precursor lesions. 61 54
10620396 1999
4
[Prognosis and invasion marker expression of cutaneous melanoma. Metastasis-associated genes (nm23, CD44v3, MMP2]. 54 61
10064977 1999
5
Association between NM23-H1 gene expression and metastasis of human uveal melanoma in an animal model. 54 61
8843913 1996
6
Biodistribution studies of boronophenylalanine in different types of skin melanoma. 61
32561053 2020
7
ZEB and Snail expression indicates epithelial-mesenchymal transition in canine melanoma. 61
32278962 2020
8
Engineering and biological assessment of double core nanoplatform for co-delivery of hybrid fluorophores to human melanoma. 61
32446020 2020
9
Regressive melanoma in a female patient: A case report. 61
32508999 2020
10
[Immunotherapy for malignant melanoma]. 61
32462249 2020
11
Adjuvant Therapy for Cutaneous Melanoma. 61
32482320 2020
12
Development and validation of autophagy-related-gene biomarker and nomogram for predicting the survival of cutaneous melanoma. 61
32080971 2020
13
The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma. 61
32439398 2020
14
Age and Melanocytic Lesions. 61
32482314 2020
15
No generally increased risk of cancer after total hip arthroplasty performed due to osteoarthritis. 61
31595487 2020
16
Association between tumor characteristics and second primary cancers with cutaneous melanoma survival: A nationwide cohort study. 61
32012479 2020
17
Melanoma Characteristics in Patients with a History of UV Tanning Bed Usage. 61
32028781 2020
18
Mining database for the expression and gene regulation network of JAK2 in skin cutaneous melanoma. 61
32234492 2020
19
Cranial nerve outcomes in regionally recurrent head & neck melanoma after sentinel lymph node biopsy. 61
31441955 2020
20
Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review. 61
32473511 2020
21
Biophysical insights into the interaction of human serum albumin with Cassia fistula leaf extracts inspired biogenic potent antibacterial and anticancerous gold nanoparticles. 61
32567502 2020
22
Knowledge, practice and attitude about photodynamic therapy use among practicing nurses: A large scale cross-sectional data on implementation of photodynamic therapy education. 61
32278763 2020
23
Melanoma Risk and Melanocyte Biology. 61
32346747 2020
24
Pre-clinical modeling of cutaneous melanoma. 61
32504051 2020
25
Cutaneous Melanoma - A Review of Systemic Therapies. 61
32346745 2020
26
Conjunctival Melanoma: Current Treatments and Future Options. 61
31965542 2020
27
Obesity and the Impact on Cutaneous Melanoma: Friend or Foe? 61
32549336 2020
28
Anxiety and depression after diagnosis of high-risk primary cutaneous melanoma: a 4-year longitudinal study. 61
32519121 2020
29
Geographic Variations in Cutaneous Melanoma Distribution in the Russian Federation. 61
32506063 2020
30
Why is the Cutaneous Melanoma Mortality Rate not Falling? 61
32507652 2020
31
Transcription from a gene desert in a melanoma porcine model. 61
32529263 2020
32
National Comprehensive Analysis of Characteristics of Acral Lentiginous Melanoma. 61
32487638 2020
33
One-Step Surgical Removal of a Cutaneous Melanoma: Current Evidence. 61
32553988 2020
34
The Quality of Practice Guidelines for Melanoma: A Methodologic Appraisal with the AGREE II and AGREE-REX Instruments. 61
32570843 2020
35
Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. 61
31990790 2020
36
Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. 61
32530761 2020
37
Epidemiology of cutaneous melanoma and melanoma in situ: a 10-year nationwide retrospective cohort study in South Korea. 61
32356958 2020
38
Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. 61
32483240 2020
39
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. 61
32534242 2020
40
Combining texture features of whole slide images improves prognostic prediction of recurrence-free survival for cutaneous melanoma patients. 61
32546168 2020
41
Genetic variants in PDSS1 and SLC16A6 of the ketone body metabolic pathway predict cutaneous melanoma-specific survival. 61
32232919 2020
42
Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. 61
31506954 2020
43
Comment on: Effect of delay between nuclear medicine scanning and sentinel node biopsy on outcome in patients with cutaneous melanoma. 61
32379341 2020
44
The tumor immune microenvironmental analysis of 2,033 transcriptomes across 7 cancer types. 61
32533054 2020
45
Checkpoint inhibitor-induced sarcoid choroidal granulomas. 61
32195443 2020
46
Eruptive Halo Naevi: A Possible Indicator of Malignant Disease in a Case Series of Post-Adolescent Patients. 61
32556340 2020
47
Cytotoxic and proapoptotic effect of doxycycline - An in vitro study on the human skin melanoma cells. 61
32044399 2020
48
Variation in cancer survival between hospital districts and within them in Finland. 61
32552300 2020
49
Clinical, environmental, and histological distribution of BRAF, NRAS and TERT promoter mutations among cutaneous melanoma patients. A retrospective study of 563 patients. 61
32506424 2020
50
Melanoma Genomics. 61
32346746 2020

Variations for Skin Melanoma

Cosmic variations for Skin Melanoma:

9 (show top 50) (show all 4660)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM96588509 ZNF451 skin,neck,malignant melanoma,NS c.2114T>G p.I705S 6:57148199-57148199 18
2 COSM143038077 YAP1 skin,neck,malignant melanoma,NS c.1303C>T p.Q435* 11:102229716-102229716 18
3 COSM97229917 XRCC6 skin,scalp,malignant melanoma,NS c.1054C>T p.P352S 22:41650816-41650816 18
4 COSM97227877 XRCC6 skin,scalp,malignant melanoma,NS c.238C>T p.R80* 22:41636155-41636155 18
5 COSM97231271 XRCC6 skin,scalp,malignant melanoma,NS c.1422-1G>T p.? 22:41658251-41658251 18
6 COSM91384800 WT1 skin,scalp,malignant melanoma,NS c.732C>T p.F244= 11:32428534-32428534 18
7 COSM91378277 WT1 skin,scalp,malignant melanoma,NS c.1457G>A p.W486* 11:32389155-32389155 18
8 COSM91367549 WT1 skin,neck,malignant melanoma,NS c.1373G>A p.R458Q 11:32392031-32392031 18
9 COSM91384784 WT1 skin,scalp,malignant melanoma,NS c.742G>A p.D248N 11:32428524-32428524 18
10 COSM91366590 WT1 skin,scalp,malignant melanoma,NS c.1492G>A p.E498K 11:32389120-32389120 18
11 COSM91365011 WT1 skin,scalp,malignant melanoma,NS c.1024G>A p.D342N 11:32400022-32400022 18
12 COSM91365417 WT1 skin,scalp,malignant melanoma,NS c.855G>A p.L285= 11:32427973-32427973 18
13 COSM91377636 WT1 skin,scalp,malignant melanoma,NS c.1041C>T p.P347= 11:32400005-32400005 18
14 COSM85457825 WRN skin,neck,malignant melanoma,NS c.1785C>A p.I595= 8:31090898-31090898 18
15 COSM85455919 WRN skin,scalp,malignant melanoma,NS c.866C>T p.S289L 8:31080893-31080893 18
16 COSM85461009 WRN skin,scalp,malignant melanoma,NS c.3898C>T p.P1300S 8:31157446-31157446 18
17 COSM84687654 VAT1L skin,scalp,malignant melanoma,NS c.503C>T p.A168V 16:77825385-77825385 18
18 COSM84688238 VAT1L skin,scalp,malignant melanoma,NS c.430G>A p.E144K 16:77825312-77825312 18
19 COSM84678743 VAT1L skin,scalp,malignant melanoma,NS c.985G>A p.G329S 16:77884710-77884710 18
20 COSM84680278 VAT1L skin,neck,malignant melanoma,NS c.246C>T p.F82= 16:77816933-77816933 18
21 COSM88838216 USP9X skin,scalp,malignant melanoma,NS c.4006T>C p.F1336L 23:41196279-41196279 18
22 COSM88835558 USP9X skin,scalp,malignant melanoma,NS c.5216C>T p.T1739I 23:41214594-41214594 18
23 COSM89726698 UGT1A9 skin,scalp,malignant melanoma,NS c.856-6491G>A p.? 2:233760543-233760543 18
24 COSM98064686 UGT1A8 skin,scalp,malignant melanoma,NS c.856-6491G>A p.? 2:233760543-233760543 18
25 COSM97950128 UGT1A7 skin,scalp,malignant melanoma,NS c.856-6491G>A p.? 2:233760543-233760543 18
26 COSM86926830 UGT1A6 skin,scalp,malignant melanoma,NS c.862-6491G>A p.? 2:233760543-233760543 18
27 COSM97898735 UGT1A5 skin,scalp,malignant melanoma,NS c.868-6491G>A p.? 2:233760543-233760543 18
28 COSM97877826 UGT1A4 skin,scalp,malignant melanoma,NS c.868-6491G>A p.? 2:233760543-233760543 18
29 COSM117399481 UGT1A3 skin,scalp,malignant melanoma,NS c.868-6491G>A p.? 2:233760543-233760543 18
30 COSM89709626 UGT1A10 skin,scalp,malignant melanoma,NS c.856-6491G>A p.? 2:233760543-233760543 18
31 COSM86958758 UGT1A1 skin,scalp,malignant melanoma,NS c.256G>A p.E86K 2:233760543-233760543 18
32 COSM131092355 TSHR skin,scalp,malignant melanoma,NS c.2043C>T p.F681= 14:81144101-81144101 18
33 COSM131087149 TSHR skin,scalp,malignant melanoma,NS c.291C>T p.F97= 14:81068302-81068302 18
34 COSM87030927 TSC2 skin,scalp,malignant melanoma,NS c.2632C>T p.P878S 16:2075885-2075885 18
35 COSM87047212 TSC2 skin,scalp,malignant melanoma,NS c.2109G>A p.W703* 16:2072252-2072252 18
36 COSM87027807 TSC2 skin,neck,malignant melanoma,NS c.626C>T p.T209I 16:2056222-2056222 18
37 COSM87027367 TSC2 skin,scalp,malignant melanoma,NS c.3347C>T p.A1116V 16:2079619-2079619 18
38 COSM85728352 TSC1 skin,scalp,malignant melanoma,NS c.995C>T p.S332F 9:132911487-132911487 18
39 COSM85722370 TSC1 skin,scalp,malignant melanoma,NS c.248C>T p.A83V 9:132925702-132925702 18
40 COSM94305848 TRRAP skin,neck,malignant melanoma,NS c.4150G>C p.E1384Q 7:98937194-98937194 18
41 COSM94331424 TRRAP skin,scalp,malignant melanoma,NS c.6817A>G p.M2273V 7:98964637-98964637 18
42 COSM94324996 TRRAP skin,scalp,malignant melanoma,NS c.8205G>A p.E2735= 7:98976749-98976749 18
43 COSM94326030 TRRAP skin,scalp,malignant melanoma,NS c.5170C>G p.R1724G 7:98950119-98950119 18
44 COSM94305835 TRRAP skin,neck,malignant melanoma,NS c.3048G>A p.K1016= 7:98927239-98927239 18
45 COSM94313279 TRRAP skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 7:98930064-98930064 18
46 COSM94305873 TRRAP skin,neck,malignant melanoma,NS c.9803C>T p.P3268L 7:98992171-98992171 18
47 COSM94313428 TRRAP skin,scalp,malignant melanoma,NS c.3310G>A p.E1104K 7:98930123-98930123 18
48 COSM94305826 TRRAP skin,neck,malignant melanoma,NS c.687C>T p.P229= 7:98899475-98899475 18
49 COSM94320883 TRRAP skin,scalp,malignant melanoma,NS c.3407C>T p.P1136L 7:98930646-98930646 18
50 COSM94322324 TRRAP skin,scalp,malignant melanoma,NS c.1568C>T p.P523L 7:98910273-98910273 18

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 TP53 PTEN NRAS MDM2 FGF2 ERBB2
2
Show member pathways
13.88 TP53 PTEN NRAS MMP2 MDM2 FGF2
3
Show member pathways
13.76 TP53 NRAS MMP2 MDM2 FGF2 ERBB2
4
Show member pathways
13.46 TP53 PTEN NRAS MDM2 FGF2 ERBB2
5
Show member pathways
13.41 TP53 NRAS MMP2 FGF2 ERBB2 CDKN1A
6
Show member pathways
13.15 TP53 PTEN MDM2 FGF2 ERBB2 CDKN1A
7
Show member pathways
13.1 TP53 PTEN NRAS MDM2 FGF2 BRAF
8
Show member pathways
13.05 TP53 PTEN NRAS MDM2 FGF2 ERBB2
9
Show member pathways
13.01 TP53 NRAS MDM2 FGF2 CDKN2A CDKN1A
10
Show member pathways
12.97 TYR NRAS MITF CDKN2B CDKN2A CDKN1A
11
Show member pathways
12.92 TP53 PTEN NRAS MDM2 ERBB2 CDKN2A
12 12.84 TP53 NRAS FGF2 ERBB2 CASP3 BRAF
13
Show member pathways
12.81 TP53 PTEN NRAS MDM2 FGF2 ERBB2
14
Show member pathways
12.8 TP53 PTEN NRAS FGF2 ERBB2 CDKN2B
15
Show member pathways
12.79 TP53 PTEN NRAS ERBB2 CASP3 BRAF
16
Show member pathways
12.78 TP53 NRAS MDM2 CDKN2A CDKN1A CASP3
17
Show member pathways
12.7 TP53 PTEN NRAS MDM2 FGF2 ERBB2
18
Show member pathways
12.66 TP53 NRAS MMP2 FGF2 ERBB2 CDKN1A
19
Show member pathways
12.62 TP53 MDM2 CDKN2B CDKN2A CDKN1A
20 12.59 TP53 PTEN NRAS MDM2 ERBB2 CDKN2A
21
Show member pathways
12.58 TP53 PTEN NRAS MDM2 FGF2 CASP3
22
Show member pathways
12.57 TP53 PTEN NRAS ERBB2 BRAF
23
Show member pathways
12.51 TP53 NRAS MDM2 ERBB2 CASP3
24
Show member pathways
12.46 TP53 PTEN MDM2 CDKN2A CDKN1A CASP3
25 12.45 TP53 MDM2 CDKN2B CDKN2A CDKN1A
26
Show member pathways
12.43 TP53 PTEN MDM2 CDKN1A
27 12.42 TP53 PTEN NRAS CDKN2B CDKN2A CDKN1A
28
Show member pathways
12.39 TP53 CDKN2B CDKN2A CDKN1A
29
Show member pathways
12.39 TP53 PTEN MMP2 MDM2 ERBB2 CDKN1A
30 12.39 TP53 NRAS MDM2 CDKN2B CDKN2A CDKN1A
31
Show member pathways
12.34 TP53 NRAS CASP3 BRAF
32
Show member pathways
12.34 TP53 PTEN MDM2 CDKN1A CASP3
33
Show member pathways
12.33 TP53 PTEN NRAS MMP2 MITF MDM2
34 12.31 TP53 MITF MDM2 CDKN1A
35
Show member pathways
12.3 TP53 PTEN NRAS MDM2 ERBB2 CDKN1A
36 12.27 TP53 MMP2 CDKN1A CASP3 BRAF
37 12.23 TP53 PTEN MDM2 CASP3 BRAF
38 12.22 TP53 NRAS MMP2 MDM2 FGF2 ERBB2
39
Show member pathways
12.19 TP53 NRAS CASP3 BRAF
40 12.19 TP53 PTEN NRAS MDM2 CDKN2B CDKN2A
41
Show member pathways
12.18 PTEN NRAS MDM2 CDKN2B CDKN1A BRAF
42 12.16 TP53 PTEN NRAS MMP2 MITF MDM2
43 12.15 TP53 PTEN MMP2 MDM2 CDKN1A
44 12.06 TP53 MMP2 FGF2 CDKN1A
45 12.06 TP53 PTEN MDM2 CDKN2A CDKN1A BRAF
46 12.01 TP53 PTEN NRAS MDM2 ERBB2 CDKN2A
47 11.96 TP53 PTEN NRAS MDM2 CDKN2A CDKN1A
48 11.95 TP53 PTEN CDKN2B CDKN1A CASP3
49 11.88 PTEN MDM2 CDKN1A
50 11.87 TP53 MDM2 CDKN1A

GO Terms for Skin Melanoma

Cellular components related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 TYR TP53 PTEN MMP2 MITF MDM2

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.02 TP53 PTEN CDKN2B CDKN2A CDKN1A
2 response to drug GO:0042493 9.97 TP53 PTEN MDM2 CDKN1A CASP3
3 MAPK cascade GO:0000165 9.96 NRAS FGF2 ERBB2 BRAF
4 angiogenesis GO:0001525 9.94 PTEN MMP2 MCAM FGF2
5 cytokine-mediated signaling pathway GO:0019221 9.93 TP53 MMP2 FGF2 CDKN1A CASP3
6 protein stabilization GO:0050821 9.91 TP53 PTEN CDKN2A CDKN1A
7 negative regulation of apoptotic process GO:0043066 9.91 TP53 PTEN MITF MDM2 CDKN1A CASP3
8 cell cycle arrest GO:0007050 9.86 TP53 CDKN2B CDKN2A CDKN1A
9 response to organic substance GO:0010033 9.83 PTEN CDKN1A CASP3
10 regulation of protein stability GO:0031647 9.8 PTEN CDKN2A CASP3
11 positive regulation of gene expression GO:0010628 9.8 TP53 PTEN MITF MDM2 ERBB2 CDKN2A
12 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.77 TP53 MDM2 CDKN1A
13 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.77 MMP2 MDM2 FGF2
14 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.73 PTEN CDKN2B CDKN2A CDKN1A
15 cellular response to gamma radiation GO:0071480 9.7 TP53 MDM2 CDKN1A
16 response to antibiotic GO:0046677 9.69 TP53 MDM2 CASP3
17 cellular senescence GO:0090398 9.67 CDKN2B CDKN2A CDKN1A
18 response to arsenic-containing substance GO:0046685 9.65 PTEN CDKN1A
19 melanin biosynthetic process GO:0042438 9.65 TYR PMEL
20 response to X-ray GO:0010165 9.65 TP53 CDKN1A CASP3
21 amyloid fibril formation GO:1990000 9.64 MDM2 CDKN2A
22 negative regulation of fibroblast migration GO:0010764 9.63 FGF2 BRAF
23 negative regulation of phosphorylation GO:0042326 9.63 CDKN2B CDKN2A CDKN1A
24 heart development GO:0007507 9.63 TP53 PTEN MDM2 ERBB2 CDKN1A CASP3
25 cellular response to UV-C GO:0071494 9.62 TP53 MDM2
26 response to UV GO:0009411 9.62 TYR TP53 CDKN1A CASP3
27 regulation of axon regeneration GO:0048679 9.61 PTEN BRAF
28 signal transduction by p53 class mediator GO:0072331 9.58 TP53 CDKN1A
29 negative regulation of immature T cell proliferation in thymus GO:0033088 9.58 ERBB2 CDKN2A
30 replicative senescence GO:0090399 9.58 TP53 CDKN2A CDKN1A
31 cellular response to actinomycin D GO:0072717 9.55 TP53 MDM2
32 Ras protein signal transduction GO:0007265 9.35 TP53 NRAS FGF2 CDKN2A CDKN1A
33 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.02 PTEN CDKN2B CDKN2A CDKN1A CASP3

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.76 TYR TP53 PTEN PMEL MDM2 FGF2
2 protein kinase binding GO:0019901 9.65 TP53 PTEN CDKN2B CDKN2A CDKN1A
3 disordered domain specific binding GO:0097718 9.13 TP53 MDM2 CDKN2A
4 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.92 CDKN2B CDKN2A CDKN1A CASP3

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....